Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

7.71
-0.1900-2.41%
Post-market: 7.710.00000.00%16:05 EDT
Volume:1.71M
Turnover:13.22M
Market Cap:1.23B
PE:-6.31
High:7.96
Open:7.79
Low:7.62
Close:7.90
Loading ...

Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
21 Apr

Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24%

Simply Wall St.
·
15 Apr

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
12 Apr

Ocular Therapeutix Initiated at Outperform by William Blair

Dow Jones
·
08 Apr

William Blair Initiates Ocular Therapeutix With Outperform Rating

MT Newswires Live
·
08 Apr

Ocular Therapeutix initiated with an Outperform at William Blair

TIPRANKS
·
08 Apr

Top Premarket Decliners

MT Newswires Live
·
02 Apr

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

GlobeNewswire
·
31 Mar

Ocular Therapeutix Initiated at Outperform by RBC Capital

Dow Jones
·
18 Mar

Ocular Therapeutix (OCUL) Gets a Buy from RBC Capital

TIPRANKS
·
18 Mar

Why Ocular Therapeutix Was Bumping Higher This Week

Motley Fool
·
14 Mar

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Benzinga
·
12 Mar

Needham Initiates Ocular Therapeutix at Buy With $15 Price Target

MT Newswires Live
·
11 Mar

Ocular Therapeutix Initiated at Buy by Needham

Dow Jones
·
11 Mar

Ocular Therapeutix initiated with a Buy at Needham

TIPRANKS
·
11 Mar

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Mar

Stock Track | Ocular Therapeutix Soars 5% as AXPAXLI Trial Updates Boost Dosing Flexibility Prospects, Timelines

Stock Track
·
04 Mar

Ocular Therapeutix Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
04 Mar

Scotiabank Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

TIPRANKS
·
04 Mar

Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar